{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MEHTSOP051 DSURs 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT DEVELOPMENT SAFETY UPDATE REPORTS"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP051"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th12 December 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th11 December 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins, R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "08/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director, Clinical Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: December 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MEHTSOP051 DSURs 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 13,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Sharon Reid"
                    },
                    {
                        "text": "Renal research nurse"
                    },
                    {
                        "text": "03/07/2019 08/07/2019"
                    },
                    {
                        "text": "Helen Espline"
                    },
                    {
                        "text": "Primary Care research nurse"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "MEHTSOP004 SAEs (Sponsored)"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "prefix": 19.0,
                "text": "Page  of"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Applicable"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Related documents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1 - Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2 - Example DSUR"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "text": "Appendix 3 \u2013 Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This document sets out the procedures to be followed by all Mid Essex Hospital Services NHS (MEHT) staff who are involved in the preparation, review or dissemination of progress reports for ethics committees and regulatory bodies (including but not limited to the Medicines and Healthcare products Regulatory Agency (MHRA)) for MEHT sponsored studies. These progress reports include annual reports and Development Safety Update Reports (DSURs)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "It is a requirement of ethical and regulatory approval that annual reports are submitted."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 1.3,
                "text": "It aims to provide clear guidance on the timing and content of DSURs to ensure compliance with the regulatory bodies."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "This document defines the Trust's research procedures for the preparation and submission of periodic safety reporting and annual reports including DSURs for research studies and clinical trials sponsored by MEHT."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "The document clarifies the requirements for safety reporting to the regulatory authorities so as to aid compliance with Good Clinical Practice (GCP)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 2.3,
                "text": "The document aims to provide clear guidance on when and how to prepare annual reports and DSURs so as to comply with the regulatory requirements. The DSUR is a standard document for the periodic reporting on drugs under development (included marketed drugs that are under further study)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 2.4,
                "text": "The objective of the DSUR is to provide a comprehensive review and evaluation of the pertinent safety information collected during the reporting period. This will:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Examine whether the information obtained by the Sponsor during the reporting period is in accordance with previous knowledge of the drug's safety"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Describe any new safety issues"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Summarise the current understanding and management of the known and potential risks"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Provide and update on the status of the clinical investigation/development programme and study results"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "The submission of safety reports is delegated by the Sponsor to the Chief Investigator (CI) or Delegated Individual (DI) and their study team involved in the managements of MEHT sponsored Clinical Trials for an Investigational Medicinal Product (CTIMPs)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "prefix": 3.2,
                "text": "The study team can include, but is not limited to, Unit Heads, Chief Investigators (CI), Principal Investigators (PI), Co-Investigators, Consultants, Clinical Trial Pharmacists, Research Managers, Statisticians, Research Nurses, Research Midwives, Allied Health Professionals, Trial Coordinators & Data Managers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "The trial Sponsor is responsible for the preparation, content and submission of the annual reports/DSUR although they may delegate the actual task to a competent member of the study team. This delegation must be on the Sponsor/CI delegation log."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "PROCEDURE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Annual Reporting period and Development International Birth Date (DIBD)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "text": "5.1.1 The \u201cDevelopment International Birth Date\u201d (DIBD) is used to determine the start of the annual period for the DSUR. This date is the Sponsor's first authorisation to conduct a clinical trial in any country worldwide. The start of the annual period for the DSUR is the month and date of the DIBD."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "text": "5.1.2 The start of the Annual Reporting Period will be the month and date of the DIBD. For clinical trials that commenced before 1 May 2004, the reporting period starts with the issue date of the Clinical Trial Exemption (CTX) letter or first Doctors and Dentists Exemption (DDX) letter by the MHRA."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "5.1.3. Where the same Investigational Medicinal Product (IMP) is used in different trials, the data will be provided by indication."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Data-Lock date"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "5.2.1 The data lock point of the DSUR should be the last day of the one-year reporting period. For administrative convenience, if desired by the Sponsor, the data lock point of the DSUR can be designated as the last day of the month prior to the month of the DIBD."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "5.2.2 The DSUR should be submitted to all concerned regulatory authorities no later than 60 calendar days after the DSUR data lock point."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "Preparation of the DSUR and co-ordinated responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "5.3.1 The Sponsor of a clinical trial is considered responsible for the preparation, content and submission of a DSUR. The Sponsor can delegate the preparation of the DSUR to a third party (e.g. a contract research organisation)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "5.3.2 The CI/DI will complete their relevant sections and return to the R&D Department. The delegated member of the research team will also send all appendices to the R&D Department."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "5.3.3 The R&D Department will compile all the relevant information then forward the DSUR to the MHRA and the Research Ethics Committee (REC) with a final copy sent to the research teams."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 1,
                "text": "5.3.4 The final documents are to be stored in the Trial Master File (TMF)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 1,
                "prefix": 5.4,
                "text": "Completion of the DSUR"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "5.4.1 The CI will receive a reminder email from the R&D Department on the anniversary of the trial's Clinical Trials Authorisation (CTA)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "prefix": 2.0,
                "text": "5.4.2 Guidance for completion of the DSUR is available on the MHRA web site. DSUR completion guidelines. For report template, please see Appendix"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "5.4.3 The R&D Department will be the point of contact going forward for all questions/queries related to the completion and submission of the DSUR."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "5.4.4 The DSUR contains sections for completion by the CI/trial team and sections for completion by the Sponsor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "5.4.5 The CI/DI should complete those sections marked for their attention in the template."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "5.4.6 The R&D Department will then complete those sections that are for the Sponsor's attention, check that the instructions in the template have been appropriately followed and the current approved Reference Safety Information (RSI) has been used."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "text": "5.4.7 The draft DSUR must be provided to the R&D Office 2 weeks prior to the submission deadline."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "text": "5.4.8 Any necessary alterations agreed are made by the CI or the R&D Department in the relevant sections."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "text": "5.4.9 The final DSUR will then be reviewed and signed by the Sponsor's representative in the R&D Department and the CI."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "text": "5.4.10 The R&D Department will submit the DSUR and the supporting documents i.e. cover letter, approved RSI, publications and abstracts (as applicable) via the Common European Submission Portal (CESP), the online portal for MHRA submissions."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "text": "5.4.11 The R&D Department will provide the CI/trial team with a copy of the full DSUR submission for submission to the REC and for filing in the TMF."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "text": "5.4.12 It is the responsibility of the CI to provide the DSUR and accompanying documents (including the Safety Report Form) to the REC which gave favourable opinion for the trial, via email"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "5.4.13 The R&D Department will file a copy of the CESP upload email as confirmation that the DSUR has been submitted to the MHRA."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "text": "5.4.14 When received, a copy will be filed in the Sponsor file and the original confirmation forwarded to the trial team for filing in the TMF."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "DSURs for combination therapy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "5.5.1 DSURs are IMP-specific and it is the Sponsor's responsibility to ensure a single DSUR is submitted for individual IMPs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "5.5.2 In cases of multi-drug therapy trials, where it is not possible to submit DSURs for individual IMPs, a delegated member of the R&D Department in conjunction with the PI or CI will arrange to prepare a DSUR for the multi-drug therapy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 1,
                "prefix": 5.6,
                "text": "Submission of the final DSUR"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "Ensure that all the original reports are signed and dated appropriately."
            }
        },
        {
            "type": "table",
            "sequence_num": 71,
            "data": {
                "num_rows": 5,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "DSUR Submission"
                    },
                    {
                        "text": "Annual Progress Report (APR) Submission"
                    },
                    {
                        "text": "Send DSUR to the MHRA via CESP (refer to the MHRA website for current requirements)"
                    },
                    {
                        "text": "Send completed and signed APR form to the REC via email"
                    },
                    {
                        "text": "Include covering letter and all appendices"
                    },
                    {
                        "text": "No covering letter"
                    },
                    {
                        "text": "Send a copy of the DSUR to the REC on disc or via email accompanied by the REC CTIMP safety report form"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Make two copies of all the signed documents, one set for filing in the TMF and send the second set to the R&D Department for inclusion in the Sponsor files"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 1,
                "prefix": 5.7,
                "text": "Annual Progress Reports Submitted to the REC Only"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "5.7.1 It is a requirement for continued favourable opinion from the REC that an APR be submitted annually, i.e. within 30 days of the anniversary date of favourable opinion for the study which was received from the REC."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "text": "5.7.2 The APR Form for CTIMPs published on the HRA website must be used:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The  CI  will  receive  a  reminder  email  from  the  R&D  Department  on  the anniversary of the \u2018favourable opinion' from the REC for their trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "\u25cf If any extension to the duration of the trial is required, this must be included in the APR as notification of the extension to the REC"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "\u25cf A final signed copy of the APR and submission email must be submitted to the R&D Department for review and inclusion in the Sponsor file"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "text": "5.7.3 The trial team should notify participating sites of any changes in the duration of the trial as stated in the APR as soon as possible normally within 10 working days of submission."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "text": "5.7.4 The trial team should request participating sites to acknowledge the receipt of the APR form. A copy of the APR and acknowledgement of receipt from the REC should be filed in the Sponsor file and in the Trial Master File (TMF)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "RELATED DOCUMENTS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "text": "\u25cf The Development Safety Update Report (DSUR) Guidance \u2013 ICH E2F"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "text": "\u25cf For information on submission to the MHRA please refer to the MHRA website"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "\u25cf For information on submission to the HRA (REC) please refer to the HRA website"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "REFERENCES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "text": "ICH GCP"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix 3)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial - Any investigation in human subjects, other than a non-interventional trial intended to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal product or to identify any adverse reactions to one or more such products and to study absorption, distribution metabolism and excretion in one of more such products with the object of ascertaining the safety or efficacy of those products."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial of an Investigational Medicinal Product (CTIMP) - This is defined as any Clinical Research Study which intends to generate new information about the safety or efficacy of a Medicinal Product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 1,
                "text": "Data Lock Point"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "This should be the last day of the one year reporting period and the Development Update Safety Report (DSUR) should be submitted to the Medicines and Healthcare Regulatory Authority (MHRA) and the Research Ethics Committee (REC) no later than 60 days after the data lock date."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 1,
                "text": "Delegated Individual (DI)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "text": "An individual delegated by a person of responsibility to carry out their task(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 1,
                "text": "Good Clinical Practice (GCP)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "text": "The principles of Good Clinical Practice in Clinical Trials as set down in Articles 2-5 of the GCP Directive and implemented in the UK by Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I.2004/1031) as amended by S.I. 2006/1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "Good Clinical Practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 1,
                "text": "International Conference on Harmonisation (ICH)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use is a joint initiative involving both regulators and research- based industry focusing on the technical requirements for medicinal products containing new drugs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 1,
                "text": "Investigational Medicinal Product (IMP)  means a pharmaceutical form of an active substance or placebo being tested, or to be tested, or used, or to be used, as a reference in a clinical trial, and includes a medicinal product which has a marketing authorization but is, for the purposes of the trial\u2014"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "a) used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorization,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "b) used for an indication not included in the summary of product characteristics under the authorization for that product, or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "text": "c) used to gain further information about the form of that product as authorised under the authorization;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 1,
                "text": "Sponsor's Representative"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "The Director of the R&D Department will appoint an appropriate staff member to act as the Sponsor's representative."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 1,
                "text": "The Medicines & Healthcare products Regulatory Agency (MHRA)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "text": "The government agency responsible for ensuring that medicines and medical devices work, and are acceptably safe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "text": "The MHRA can also be defined as:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "MHRA (Medicines) is the competent authority for the UK in relation to the EU Directive and the Clinical Trials Regulations. MHRA (Devices) is the competent authority for the UK in relation to the Medical Devices Regulations 2002."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 1,
                "text": "The Regulations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "prefix": 1928.0,
                "text": "Medicines for Human Use (Clinical Trial) Regulations 2004 transposed the EU Clinical Trials Directive into UK legislation, as Statutory Instrument 2004 no 1031. This became effective on the 1st May 2004. An amendment to implement Directive 2005/28/EC was made to the Regulations as Statutory Instrument 2006 no"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 1,
                "text": "Trial Master File"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 0,
                "text": "The Trial Master File (TMF) will be held at the principal site by the Sponsor, Chief Investigator or at the co-ordinating centre. The TMF should contain all essential documents defined as documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. A TMF should be set up at the beginning of a trial and maintained up-to-date throughout the trial until trial conclusion."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "For trials currently running, it is recommended that Section 8 of the ICH-GCP Guideline is followed as guidance in order to meet statutory requirements. However, some of the documents listed may not be available or applicable in many non-commercial trials. The appropriate documentation will vary according to the trial and sponsor requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2 - Example DSUR"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 1,
                "text": "Development Safety Update Report Report Number:"
            }
        },
        {
            "type": "image",
            "sequence_num": 119,
            "data": {
                "url": "MEHTSOP051 DSURs 1.0.004.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 1,
                "text": "Trial Title: Reporting Period:"
            }
        },
        {
            "type": "image",
            "sequence_num": 121,
            "data": {
                "url": "MEHTSOP051 DSURs 1.0.006.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 122,
            "data": {
                "num_rows": 6,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Name of IMP"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Sponsor"
                    },
                    {
                        "text": "Mid Essex Hospital Services NHS Trust"
                    },
                    {
                        "text": "Chief Investigator"
                    },
                    {
                        "text": "Mid Essex Hospital Services NHS Trust Broomfield Hospital Court Road, Chelmsford Essex, CM1 7ET"
                    },
                    {
                        "text": "Sponsor Address"
                    },
                    {
                        "text": "Mid Essex Hospital Services NHS Trust Broomfield Hospital Court Road, Chelmsford Essex, CM1 7ET"
                    },
                    {
                        "text": "Chief Investigator Address"
                    },
                    {
                        "text": "Mid Essex Hospital Services NHS Trust Broomfield Hospital Court Road, Chelmsford Essex, CM1 7ET"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 1,
                "text": "This  report  contains  confidential  information  and  should  not  be  shared  or distributed without the approval of the sponsor"
            }
        },
        {
            "type": "table",
            "sequence_num": 124,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Executive Summary"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 1,
                "text": "Table of Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "Cumulative Subject Exposure in the Development Programme"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 0,
                "prefix": 6.2,
                "text": "Patient Exposure from Marketing Experience"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "Reference Information"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "prefix": 7.2,
                "text": "Line Listings of Serious Adverse Reactions during the Reporting Period"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 0,
                "prefix": 7.3,
                "text": "Cumulative Summary Tabulations of Serious Adverse Events"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "Completed Clinical Trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 0,
                "prefix": 8.2,
                "text": "Ongoing Clinical Trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 0,
                "prefix": 8.3,
                "text": "Long-term Follow-up"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 0,
                "prefix": 8.4,
                "text": "Other Therapeutic Use of Investigational Drug"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 0,
                "prefix": 8.5,
                "text": "New Safety Data Related to Combination Therapies"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "text": "18.1. Evaluation of the Risks"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "prefix": 18.2,
                "text": "Benefit-risk Considerations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 0,
                "text": "Appendices to the DSUR"
            }
        },
        {
            "type": "table",
            "sequence_num": 139,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Introduction"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 140,
            "data": {
                "num_rows": 3,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Worldwide Marketing Approval Status"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 141,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Actions Taken in the Reporting Period for Safety Reasons"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 142,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Changes to Reference Safety Information"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 143,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Inventory of Clinical Trials Ongoing and Completed During the Reporting Period"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 144,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Estimated Cumulative Exposure"
                    },
                    {
                        "text": "6.1 Cumulative Subject Exposure in the Development Programme: 6.2 Patient Exposure from Marketing Experience"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 145,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Data in Line Listings and Summary Tabulations"
                    },
                    {
                        "text": "7.1 Reference Information 7.2 Line Listings of Serious Adverse Reactions during the Reporting Period 7.3 Cumulative Summary Tabulations of Serious Adverse Events"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 146,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Significant Findings from Clinical Trials during the Reporting Period"
                    },
                    {
                        "text": "8.1 Completed Clinical Trials 8.2 Ongoing Clinical Trials 8.3 Long-term Follow-up 8.4 Other Therapeutic Use of Investigational Drug"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 1,
                "text": "8.5 New Safety Data Related to Combination Therapies"
            }
        },
        {
            "type": "table",
            "sequence_num": 148,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Safety Findings from Non-interventional Studies"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 149,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Other Clinical Trial/Study Safety Information"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 150,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Safety Findings from Marketing Experience"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 151,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Non-clinical Data"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 152,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Literature"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 153,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Other DSURs"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 154,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Lack of Efficacy"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 155,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Region-Specific Information"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 156,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Late Breaking Information"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 1,
                "text": "18. Overall Safety Assessment"
            }
        },
        {
            "type": "image",
            "sequence_num": 158,
            "data": {
                "url": "MEHTSOP051 DSURs 1.0.007.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 1,
                "prefix": 18.1,
                "text": "Evaluation of the Risks"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 1,
                "prefix": 18.2,
                "text": "Benefit-risk Considerations"
            }
        },
        {
            "type": "table",
            "sequence_num": 161,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Summary of Important Risks"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 162,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Conclusions"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "text": "Research & Development DSUR's / MEHTSOP051/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 0,
                "text": "Research & Development DSUR's / MEHTSOP051/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research & Development DSUR's / MEHTSOP051"
            }
        },
        {
            "type": "table",
            "sequence_num": 168,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "New SOP"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 170,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 0,
                "prefix": 19.0,
                "text": ""
            }
        }
    ]
}